Obesity is a chronic, relapsing disease driven by biological, behavioral, environmental, and social determinants affecting more than 1 billion people worldwide.1 Obesity also drives an increasing burden of comorbidities, such as type 2 diabetes, cardiovascular disease, liver and kidney disease, and several cancers.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Francesca Celletti
Toward a Healthier Future Through Obesity Prevention and Care : The JAMA Summit Report on Obesity
|
By Anne R. Cappola, Derek C. Angus, Rexford Ahima, Louis J. Aronne, Kirsten Bibbins-Domingo Verified, Lindsay Dawson, Robert F. Kushner, Mary M. McDermott, Timothy Anderson, Jamy Ard, David Arterburn, Rachel L Batterham, Kim Boyd, Jason Brett, Francesca Celletti, Rachel Cox, Deidra C. Crews, Julie M. Donohue, Gregory J. Esper, Gary Foster, Beth Frates, W. Timothy Garvey, Kimberly A. Gudzune, Jens Juul Holst, Jeffrey Huebner, John M. Jakicic, Linong Ji, Lee M. Kaplan, Dhruv S. Kazi, Samuel Klein, Lotte Bjerre Knudsen, Rekha B. Kumar, David Ludwig, T. Joseph Mattingly, Michelle McRae, Purnima Menon, Rhonda E. Monroe, John Morton, Joseph Nadglowski, Chiadi E. Ndumele, Marion Nestle, Alexis Ogdie, Francisco J Pasquel, Jennifer L. Pomeranz, Nicolaas P. Pronk, Joseph Ross, Naveed Sattar, Hilary K. Seligman, B. Gabriel Smolarz, Fatima Cody Stanford, Shannon Zenk, Hannah Park Verified, Wendy Whitehead
|
JAMA: Journal of the American Medical Association
Verified
WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults—Reply
In Reply We appreciate the close attention paid to our recently released WHO guideline on the use of GLP-1 therapies for the treatment of obesity in adults.1,2 In his Letter, Dr Redmond states that the guideline identified diabetes, hypertension, and cardiovascular risk as the primary comorbidities for stratifying patient need and highlights that obesity-associated cancer risk is an additional domain that was not explicitly mentioned in the guideline but that should be considered in this...
From endorsement of the WHO Acceleration Plan to Stop Obesity to national implementation: country progress on health system preparedness to scale up a comprehensive obesity chronic care programme
Health PolicyOnline firstOpen access Affiliations & Notes aDepartment of Nutrition and Food Safety, WHO, Geneva, Switzerland bHarvard T H Chan School of Public Health, Boston, MA, USA cInstitute of Global Health, University of Geneva, Geneva, Switzerland dThe London Borough of Camden, Camden Town Hall, London, UK eDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA fDepartment of Data, Digital and Artificial Intelligence, WHO, Geneva,...
World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults
Introduction Obesity as a global public health issue is a relatively recent but growing problem for all countries. Obesity arises from a set of complex interactions in individuals including genetics, neurobiology, and eating behaviors, as well as obesogenic environments resulting from shifts in diet, activity, and lifestyle alongside globalization and industrialization of food production and marketing.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Francesca
Contact Francesca, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack